- BeiGene ( NASDAQ: BGNE ) said that the Government of Quebec will publicly fund tyrosine kinase, Brukinsa, to treat adult patients with Waldenström's macroglobulinemia (WM), a rare blood cancer.
- BeiGene Canada said it was working with other provinces for the addition of this medication to their respective public drug plans.
- WM is responsible for changes to B-Cells, producing abnormal cells which multiply and make an excessive amount of an antibody called IgM, which causes blood to become very thick and impede flow throughout the body.
For further details see:
Quebec to fund BeiGene's Brukinsa to treat rare blood cancer